A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

← catalyst calendar

NCT07323654 · readout ≤ 499 d

Sponsored by Kymera Therapeutics, Inc. (industry) · KYMR — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

264estimated

Sites

Countries

Argentina, Germany, Poland +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-28

actual

When the study began enrolling

Primary completion

Dec 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2026-01-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Eosinophilic Asthma

Interventions

Drug: KT-621
Other: Placebo

Primary outcome

what the primary-completion date above is the date OF

Change from baseline in pre-bronchodilator FEV1

measured From baseline to Week 12

Permalink · KYMR's whole pipeline · Catalyst calendar · Every registered study · What changed